Insights / Function
Posts carrying the Business Development tag.
5 May 2026 · 3 min read
Capital depth, role mix, and integration target. Three signals that separate a real pharma AI capability build from a press-release pilot dressed up as a strategic partnership.
2 Apr 2026 · 3 min read
CRO stocks dropped sharply on AI fears: IQVIA, Medpace, Charles River. The market may be right that AI changes trial economics. It’s wrong about where the disruption lands. CROs are infrastructure companies, and AI should make them more valuable, not less — if they can break free from the cost-plus model.
31 Mar 2026 · 3 min read
Eli Lilly’s third Insilico deal in three years: $115M upfront, up to $2.75B in milestones, plus royalties. The progression from software licensing in 2023 to a $2.75B commitment in 2026 tells the real story. The signal for the rest of the AI drug discovery space is harder to read — deals like this concentrate pharma attention on proven platforms.
29 Jan 2026 · 3 min read
Hologen, Eric Schmidt’s stealth biotech-AI venture, is raising $150M at an $850M pre-money on a promise of 100% returns in 12 months. The pitch is closer to financial underwriting than AI product development. Here’s what would convince me it’s more than narrative.
20 Nov 2025 · 1 min read
Jeff Bezos just bet $106M on Profluent, a company using frontier AI models to design proteins that don't exist in nature — and I break down exactly what makes these models 'frontier' and why it matters for programmable biology.
2 Aug 2024 · 1 min read
Microsoft now formally lists OpenAI as a competitor, despite having invested $13 billion into the company — a move that may be tied to SearchGPT or antitrust optics. The strategic manoeuvres around these massive LLM-race investments are captivating.